Unknown

Dataset Information

0

Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434.


ABSTRACT: Nelarabine has shown impressive single agent clinical activity in T-cell acute lymphoblastic leukemia (T-ALL), but has been associated with significant neurotoxicities in heavily pre-treated patients. We showed previously that it was safe to add nelarabine to a BFM-86 chemotherapy backbone (AALL00P2). Children's Oncology Group (COG) AALL0434 is a Phase III study designed to test the safety and efficacy of nelarabine when incorporated into a COG augmented BFM-based regimen, which increases exposure to agents with potential neurotoxicity compared to the historical AALL00P2 regimen.AALL0434 included a safety phase to assess nelarabine toxicity. Patients with high-risk (HR) T-ALL were randomized to receive Capizzi-style escalating methotrexate (MTX) plus pegaspargase or high dose (HD) MTX with/without six five-days courses of nelarabine. We report results from 94 patients who participated in the initial safety phase of the study.There were no differences in the incidence of peripheral motor neuropathies, sensory neuropathies or central neurotoxicities among those randomized to the nelarabine (n = 47) and non-nelarabine arms (n = 47).The addition of nelarabine to COG-augmented BFM chemotherapy regimen is safe and feasible. The ongoing AALL0434 Efficacy Phase will determine whether the addition of nelarabine treatment improves outcome for patients with T-ALL.

SUBMITTER: Winter SS 

PROVIDER: S-EPMC4433576 | biostudies-literature | 2015 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434.

Winter Stuart S SS   Dunsmore Kimberly P KP   Devidas Meenakshi M   Eisenberg Nancy N   Asselin Barbara L BL   Wood Brent L BL   Leonard Rn Marcia S MS   Murphy John J   Gastier-Foster Julie M JM   Carroll Andrew J AJ   Heerema Nyla A NA   Loh Mignon L ML   Raetz Elizabeth A EA   Winick Naomi J NJ   Carroll William L WL   Hunger Stephen P SP  

Pediatric blood & cancer 20150308 7


<h4>Background</h4>Nelarabine has shown impressive single agent clinical activity in T-cell acute lymphoblastic leukemia (T-ALL), but has been associated with significant neurotoxicities in heavily pre-treated patients. We showed previously that it was safe to add nelarabine to a BFM-86 chemotherapy backbone (AALL00P2). Children's Oncology Group (COG) AALL0434 is a Phase III study designed to test the safety and efficacy of nelarabine when incorporated into a COG augmented BFM-based regimen, whi  ...[more]

Similar Datasets

| S-EPMC7526719 | biostudies-literature
| S-EPMC8763141 | biostudies-literature
| S-EPMC7479761 | biostudies-literature
| S-EPMC4779061 | biostudies-literature
| S-EPMC4220044 | biostudies-literature
| S-EPMC9242409 | biostudies-literature
| S-EPMC4872007 | biostudies-literature
| S-EPMC6067800 | biostudies-literature
| S-EPMC3053149 | biostudies-literature
| S-EPMC5403576 | biostudies-literature